<html lang="en">
<head>
<meta charset="utf-8"/>
<title offset="136">Herd immunity</title>
<script src="https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_SVG.js" type="text/javascript">
</script>
</head>
<body>
<h1>Herd immunity</h1>
<hr/>

<p><a href="Image:Community_Immunity.jpg" title="wikilink">thumb|upright=1.5|The top box shows an outbreak in a community in which a few people are infected (shown in red) and the rest are healthy but unimmunized (shown in blue); the illness spreads freely through the population. The middle box shows a population where a small number have been immunized (shown in yellow); those not immunized become infected while those immunized do not. In the bottom box, a large proportion of the population have been immunized; this prevents the illness from spreading significantly, including to unimmunized people.</a></p>

<p><strong>Herd immunity</strong> (also called <strong>herd effect</strong>, <strong>community immunity</strong>, <strong>population immunity</strong>, or <strong>social immunity</strong>) is a form of indirect protection from infectious disease that occurs when a large percentage of a population has become <a href="Immunity_(medical)" title="wikilink">immune</a> to an infection, thereby providing a measure of protection for individuals who are not immune.<a class="footnoteRef" href="#fn1" id="fnref1"><sup>1</sup></a><a class="footnoteRef" href="#fn2" id="fnref2"><sup>2</sup></a> In a population in which a large number of individuals are immune, chains of infection are likely to be disrupted, which stops or slows the spread of disease.<a class="footnoteRef" href="#fn3" id="fnref3"><sup>3</sup></a> The greater the proportion of individuals in a community who are immune, the smaller the probability that those who are not immune will come into contact with an infectious individual.<a class="footnoteRef" href="#fn4" id="fnref4"><sup>4</sup></a></p>

<p>Individual immunity can be gained through recovering from a natural infection or through artificial means such as <a class="uri" href="vaccination" title="wikilink">vaccination</a>.<a class="footnoteRef" href="#fn5" id="fnref5"><sup>5</sup></a> Some individuals cannot become immune due to medical reasons and in this group herd immunity is an important method of protection.<a class="footnoteRef" href="#fn6" id="fnref6"><sup>6</sup></a><a class="footnoteRef" href="#fn7" id="fnref7"><sup>7</sup></a> Once a certain threshold has been reached, herd immunity will gradually eliminate a disease from a population.<a class="footnoteRef" href="#fn8" id="fnref8"><sup>8</sup></a> This elimination, if achieved worldwide, may result in the permanent reduction in the number of infections to zero, called eradication.<a class="footnoteRef" href="#fn9" id="fnref9"><sup>9</sup></a> This method was used for the eradication of <a class="uri" href="smallpox" title="wikilink">smallpox</a> in 1977 and for the regional elimination of other diseases.<a class="footnoteRef" href="#fn10" id="fnref10"><sup>10</sup></a> Herd immunity does not apply to all diseases, just those that are <a href="Contagious_disease" title="wikilink">contagious</a>, meaning that they can be transmitted from one individual to another.<a class="footnoteRef" href="#fn11" id="fnref11"><sup>11</sup></a> <a class="uri" href="Tetanus" title="wikilink">Tetanus</a>, for example, is infectious but not contagious, so herd immunity does not apply.<a class="footnoteRef" href="#fn12" id="fnref12"><sup>12</sup></a></p>

<p>The term herd immunity was first used in 1923.<a class="footnoteRef" href="#fn13" id="fnref13"><sup>13</sup></a> It was recognized as a naturally occurring phenomenon in the 1930s when it was observed that after a significant number of children had become immune to <a class="uri" href="measles" title="wikilink">measles</a>, the number of new infections temporarily decreased, including among <a href="Susceptible_individual" title="wikilink">susceptible</a> children.<a class="footnoteRef" href="#fn14" id="fnref14"><sup>14</sup></a><a class="footnoteRef" href="#fn15" id="fnref15"><sup>15</sup></a> Mass vaccination to induce herd immunity has since become common and proved successful in preventing the spread of many <a href="infectious_disease" title="wikilink">infectious diseases</a>.<a class="footnoteRef" href="#fn16" id="fnref16"><sup>16</sup></a> Opposition to vaccination has posed a challenge to herd immunity, allowing preventable diseases to persist in or return to communities that have inadequate vaccination rates.<a class="footnoteRef" href="#fn17" id="fnref17"><sup>17</sup></a><a class="footnoteRef" href="#fn18" id="fnref18"><sup>18</sup></a><a class="footnoteRef" href="#fn19" id="fnref19"><sup>19</sup></a></p>
<h2 id="effects">Effects</h2>
<h3 id="protection-of-those-without-immunity">Protection of those without immunity</h3>

<p> Some individuals depend on herd immunity because they either cannot develop immunity or for medical reasons cannot be immunized.<a class="footnoteRef" href="#fn20" id="fnref20"><sup>20</sup></a> Newborn infants are too young to receive many vaccines, so they primarily rely on the adults around them to be immune.<a class="footnoteRef" href="#fn21" id="fnref21"><sup>21</sup></a> <a class="uri" href="Immunodeficiency" title="wikilink">Immunodeficiency</a> from <a class="uri" href="HIV/AIDS" title="wikilink">HIV/AIDS</a>, <a class="uri" href="lymphoma" title="wikilink">lymphoma</a>, <a class="uri" href="leukemia" title="wikilink">leukemia</a>, a <a href="bone_marrow" title="wikilink">bone marrow</a> cancer, an impaired <a class="uri" href="spleen" title="wikilink">spleen</a>, <a class="uri" href="chemotherapy" title="wikilink">chemotherapy</a>, or <a href="Radiation_therapy" title="wikilink">radiotherapy</a> may be a contraindication to some vaccines.<a class="footnoteRef" href="#fn22" id="fnref22"><sup>22</sup></a><a class="footnoteRef" href="#fn23" id="fnref23"><sup>23</sup></a><a class="footnoteRef" href="#fn24" id="fnref24"><sup>24</sup></a> Live attenuated vaccines are contraindicated for pregnant women on the theoretical grounds that the fetus could become infected, though this is not known to occur,<a class="footnoteRef" href="#fn25" id="fnref25"><sup>25</sup></a><a class="footnoteRef" href="#fn26" id="fnref26"><sup>26</sup></a> and for individuals who have recently received a <a href="blood_product" title="wikilink">blood product</a> since the product may have contained antibodies that render the vaccine ineffective.<a class="footnoteRef" href="#fn27" id="fnref27"><sup>27</sup></a> If a person has experienced <a class="uri" href="anaphylaxis" title="wikilink">anaphylaxis</a> to a vaccine or vaccine component, then it is advised that he or she not be vaccinated with that vaccine or with a vaccine that has that component.<a class="footnoteRef" href="#fn28" id="fnref28"><sup>28</sup></a><a class="footnoteRef" href="#fn29" id="fnref29"><sup>29</sup></a> Individuals in one of these groups may have lost their immunity, may not be able to become immune, or disease symptoms may be more severe in them, so these individuals generally rely on herd immunity more than others who can otherwise safely become immune via vaccination.<a class="footnoteRef" href="#fn30" id="fnref30"><sup>30</sup></a><a class="footnoteRef" href="#fn31" id="fnref31"><sup>31</sup></a><a class="footnoteRef" href="#fn32" id="fnref32"><sup>32</sup></a></p>

<p>High levels of immunity in certain age groups can create herd immunity for other age groups.<a class="footnoteRef" href="#fn33" id="fnref33"><sup>33</sup></a> <a class="uri" href="Pertussis" title="wikilink">Pertussis</a> is most severe in infants too young to be vaccinated, so vaccinating adults against the disease can protect these infants from infection.<a class="footnoteRef" href="#fn34" id="fnref34"><sup>34</sup></a><a class="footnoteRef" href="#fn35" id="fnref35"><sup>35</sup></a> This is especially important for close family members, who account for most of the transmissions to young infants.<a class="footnoteRef" href="#fn36" id="fnref36"><sup>36</sup></a><a class="footnoteRef" href="#fn37" id="fnref37"><sup>37</sup></a> Vaccinating children with pneumococcal vaccine has shown to reduce pneumococcal disease incidence in younger, unvaccinated siblings.<a class="footnoteRef" href="#fn38" id="fnref38"><sup>38</sup></a> Conversely, preferentially vaccinating children can protect older age groups from certain diseases.<a class="footnoteRef" href="#fn39" id="fnref39"><sup>39</sup></a><a class="footnoteRef" href="#fn40" id="fnref40"><sup>40</sup></a> The introduction of pneumococcal and <a href="rotavirus_vaccine" title="wikilink">rotavirus vaccines</a> for children has resulted in major declines in <a href="Streptococcus_pneumoniae" title="wikilink">pneumococcus</a>- and <a class="uri" href="rotavirus" title="wikilink">rotavirus</a>-attributable hospitalizations and deaths for not only immunized children, but also for older children and adults, who do not normally receive these vaccines.<a class="footnoteRef" href="#fn41" id="fnref41"><sup>41</sup></a><a class="footnoteRef" href="#fn42" id="fnref42"><sup>42</sup></a><a class="footnoteRef" href="#fn43" id="fnref43"><sup>43</sup></a> Even though <a class="uri" href="influenza" title="wikilink">influenza</a> (flu) is most severe in the elderly, <a href="influenza_vaccine" title="wikilink">influenza vaccines</a> are least effective in this age group, likely because of a waning of the immune system with age.<a class="footnoteRef" href="#fn44" id="fnref44"><sup>44</sup></a><a class="footnoteRef" href="#fn45" id="fnref45"><sup>45</sup></a> Flu vaccines are much more effective in children than in the elderly, so prioritizing school-age children for seasonal flu immunization can create a certain degree of herd immunity for the elderly.<a class="footnoteRef" href="#fn46" id="fnref46"><sup>46</sup></a><a class="footnoteRef" href="#fn47" id="fnref47"><sup>47</sup></a></p>

<p>For <a href="sexually_transmitted_infection" title="wikilink">sexually transmitted infections</a> (STIs), high levels of immunity in one gender induces herd immunity for both genders.<a class="footnoteRef" href="#fn48" id="fnref48"><sup>48</sup></a><a class="footnoteRef" href="#fn49" id="fnref49"><sup>49</sup></a><a class="footnoteRef" href="#fn50" id="fnref50"><sup>50</sup></a> <a href="Human_papillomavirus" title="wikilink">Human papillomavirus</a> (HPV) vaccines are primarily targeted at adolescent females who have yet to become sexually active in order to prevent new infections of <a href="cervical_cancer" title="wikilink">cervical cancer</a>-causing viruses.<a class="footnoteRef" href="#fn51" id="fnref51"><sup>51</sup></a><a class="footnoteRef" href="#fn52" id="fnref52"><sup>52</sup></a><a class="footnoteRef" href="#fn53" id="fnref53"><sup>53</sup></a> When <a href="HPV_vaccine" title="wikilink">HPV vaccine</a> uptake among females is high, significant declines in diseases caused by HPVs in males can be observed.<a class="footnoteRef" href="#fn54" id="fnref54"><sup>54</sup></a><a class="footnoteRef" href="#fn55" id="fnref55"><sup>55</sup></a><a class="footnoteRef" href="#fn56" id="fnref56"><sup>56</sup></a> However, this protection of males does not extend to homosexual males.<a class="footnoteRef" href="#fn57" id="fnref57"><sup>57</sup></a> If vaccine uptake among females is low, then immunizing adolescent males may be needed to provide sufficient protection to males.<a class="footnoteRef" href="#fn58" id="fnref58"><sup>58</sup></a><a class="footnoteRef" href="#fn59" id="fnref59"><sup>59</sup></a> Immunizing males can confer some herd immunity for females, though not as much as if females had been immunized instead.<a class="footnoteRef" href="#fn60" id="fnref60"><sup>60</sup></a> High-risk behaviors make eliminating STIs difficult since even though most infections occur among individuals with moderate risk, the majority of transmissions occur because of high-risk individuals.<a class="footnoteRef" href="#fn61" id="fnref61"><sup>61</sup></a> For this reason, and because homosexual males do not benefit from herd immunity from females, it may be necessary to immunize some males in order to establish herd immunity in certain populations.<a class="footnoteRef" href="#fn62" id="fnref62"><sup>62</sup></a><a class="footnoteRef" href="#fn63" id="fnref63"><sup>63</sup></a></p>
<h3 id="evolutionary-pressure">Evolutionary pressure</h3>

<p>Herd immunity itself acts as an <a href="evolutionary_pressure" title="wikilink">evolutionary pressure</a> on certain viruses, influencing <a href="viral_evolution" title="wikilink">viral evolution</a> by encouraging the production of novel strains, in this case referred to as escape mutants, that are able to "escape" from herd immunity and spread more easily.<a class="footnoteRef" href="#fn64" id="fnref64"><sup>64</sup></a><a class="footnoteRef" href="#fn65" id="fnref65"><sup>65</sup></a> At the molecular level, viruses escape from herd immunity through <a href="antigenic_drift" title="wikilink">antigenic drift</a>, which is when <a href="mutation" title="wikilink">mutations</a> accumulate in the portion of the <a href="Virus#Genome" title="wikilink">viral genome</a> that encodes for the virus's surface <a class="uri" href="antigen" title="wikilink">antigen</a>, typically a protein of the virus <a class="uri" href="capsid" title="wikilink">capsid</a>, producing a change in the viral <a class="uri" href="epitope" title="wikilink">epitope</a>.<a class="footnoteRef" href="#fn66" id="fnref66"><sup>66</sup></a><a class="footnoteRef" href="#fn67" id="fnref67"><sup>67</sup></a> Alternatively, the reassortment of separate viral genome segments, or <a href="antigenic_shift" title="wikilink">antigenic shift</a>, which is more common when there are more strains in circulation, can also produce new <a href="serotype" title="wikilink">serotypes</a>.<a class="footnoteRef" href="#fn68" id="fnref68"><sup>68</sup></a><a class="footnoteRef" href="#fn69" id="fnref69"><sup>69</sup></a> When either of these occur, <a href="memory_T_cell" title="wikilink">memory T cells</a> no longer recognize the virus, the virus becomes resistant to certain existing <a href="antiviral_drug" title="wikilink">antiviral drugs</a>, and herd immunity ceases to be relevant to the dominant circulating strain.<a class="footnoteRef" href="#fn70" id="fnref70"><sup>70</sup></a><a class="footnoteRef" href="#fn71" id="fnref71"><sup>71</sup></a> For both influenza and <a class="uri" href="norovirus" title="wikilink">norovirus</a>, epidemics temporarily induce herd immunity until a new dominant strain emerges, causing successive waves of epidemics.<a class="footnoteRef" href="#fn72" id="fnref72"><sup>72</sup></a><a class="footnoteRef" href="#fn73" id="fnref73"><sup>73</sup></a> As this evolution poses a challenge to herd immunity, <a href="Neutralizing_antibody#Broadly-neutralizing_antibodies" title="wikilink">broadly neutralizing antibodies</a> and "universal" vaccines that can provide protection beyond a specific serotype are in development.<a class="footnoteRef" href="#fn74" id="fnref74"><sup>74</sup></a><a class="footnoteRef" href="#fn75" id="fnref75"><sup>75</sup></a><a class="footnoteRef" href="#fn76" id="fnref76"><sup>76</sup></a></p>
<h3 id="serotype-replacement">Serotype replacement</h3>

<p>Serotype replacement, or serotype shifting, may occur if the <a class="uri" href="prevalence" title="wikilink">prevalence</a> of a specific serotype declines due to high levels of immunity, allowing other serotypes to replace it.<a class="footnoteRef" href="#fn77" id="fnref77"><sup>77</sup></a><a class="footnoteRef" href="#fn78" id="fnref78"><sup>78</sup></a> Initial vaccines against <em>Streptococcus pneumoniae</em> significantly reduced nasopharyngeal carriage of vaccine serotypes (VTs), only to be entirely offset by increased carriage of non-vaccine serotypes (NVTs).<a class="footnoteRef" href="#fn79" id="fnref79"><sup>79</sup></a><a class="footnoteRef" href="#fn80" id="fnref80"><sup>80</sup></a><a class="footnoteRef" href="#fn81" id="fnref81"><sup>81</sup></a> This did not result in an equal increase in disease incidence though since NVTs were less invasive than VTs.<a class="footnoteRef" href="#fn82" id="fnref82"><sup>82</sup></a> Since then, <a href="pneumococcal_vaccine" title="wikilink">pneumococcal vaccines</a> that provide protection from the emerging serotypes have been introduced and have successfully countered their emergence.<a class="footnoteRef" href="#fn83" id="fnref83"><sup>83</sup></a> The reduction in the prevalence of pneumococci has included <a href="Antimicrobial_resistance" title="wikilink">antibiotic-resistant</a> serotypes.<a class="footnoteRef" href="#fn84" id="fnref84"><sup>84</sup></a><a class="footnoteRef" href="#fn85" id="fnref85"><sup>85</sup></a> The possibility of future shifting remains, so further strategies to deal with this include expansion of VT coverage and the development of vaccines that use either killed whole-cells, which have more surface antigens, or proteins present in multiple serotypes.<a class="footnoteRef" href="#fn86" id="fnref86"><sup>86</sup></a><a class="footnoteRef" href="#fn87" id="fnref87"><sup>87</sup></a></p>
<h3 id="eradication-of-diseases">Eradication of diseases</h3>

<p> If herd immunity has been established and maintained in a population for a sufficient time period, then the disease will inevitably be eliminated, meaning that no more endemic transmissions will occur.<a class="footnoteRef" href="#fn88" id="fnref88"><sup>88</sup></a> If elimination is achieved worldwide and the number of cases is permanently reduced to zero, then a disease can be declared eradicated.<a class="footnoteRef" href="#fn89" id="fnref89"><sup>89</sup></a> <a href="Eradication_of_infectious_diseases" title="wikilink">Eradication</a> can thus be considered the final effect or end-result of <a href="public_health" title="wikilink">public health</a> initiatives to control the spread of infectious disease.<a class="footnoteRef" href="#fn90" id="fnref90"><sup>90</sup></a><a class="footnoteRef" href="#fn91" id="fnref91"><sup>91</sup></a> The benefits of eradication include ending all morbidity and mortality caused by the disease, financial savings for individuals, health care providers, and governments, and enabling resources used to control the disease to be used elsewhere.<a class="footnoteRef" href="#fn92" id="fnref92"><sup>92</sup></a> To date, two diseases have been eradicated using vaccination and herd immunity: smallpox and <a class="uri" href="rinderpest" title="wikilink">rinderpest</a>.<a class="footnoteRef" href="#fn93" id="fnref93"><sup>93</sup></a><a class="footnoteRef" href="#fn94" id="fnref94"><sup>94</sup></a><a class="footnoteRef" href="#fn95" id="fnref95"><sup>95</sup></a> Eradication efforts that rely on herd immunity are currently underway for <a class="uri" href="poliomyelitis" title="wikilink">poliomyelitis</a>, though civil unrest and distrust of modern medicine have made this difficult.<a class="footnoteRef" href="#fn96" id="fnref96"><sup>96</sup></a><a class="footnoteRef" href="#fn97" id="fnref97"><sup>97</sup></a> Voluntary vaccination, for a variety of reasons, may also be an obstacle to eradication if not enough people become immune.<a class="footnoteRef" href="#fn98" id="fnref98"><sup>98</sup></a><a class="footnoteRef" href="#fn99" id="fnref99"><sup>99</sup></a><a class="footnoteRef" href="#fn100" id="fnref100"><sup>100</sup></a><a class="footnoteRef" href="#fn101" id="fnref101"><sup>101</sup></a></p>
<h2 id="free-riding">Free riding</h2>

<p>Herd immunity is vulnerable to the <a href="free_rider_problem" title="wikilink">free rider problem</a>.<a class="footnoteRef" href="#fn102" id="fnref102"><sup>102</sup></a> Individuals who lack immunity, primarily those who choose not to vaccinate, free ride off the herd immunity created by those who are immune.<a class="footnoteRef" href="#fn103" id="fnref103"><sup>103</sup></a> As the number of free riders in a population increases, outbreaks of preventable diseases become more common.<a class="footnoteRef" href="#fn104" id="fnref104"><sup>104</sup></a><a class="footnoteRef" href="#fn105" id="fnref105"><sup>105</sup></a><a class="footnoteRef" href="#fn106" id="fnref106"><sup>106</sup></a> Individuals may choose to free ride for a variety of reasons, including <a href="Bandwagon_effect" title="wikilink">bandwagoning</a> or <a href="groupthink" title="wikilink">groupthinking</a>,<a class="footnoteRef" href="#fn107" id="fnref107"><sup>107</sup></a><a class="footnoteRef" href="#fn108" id="fnref108"><sup>108</sup></a> social norms or <a href="peer_pressure" title="wikilink">peer pressure</a>,<a class="footnoteRef" href="#fn109" id="fnref109"><sup>109</sup></a> religious beliefs,<a class="footnoteRef" href="#fn110" id="fnref110"><sup>110</sup></a> the perceived effectiveness of a vaccine,<a class="footnoteRef" href="#fn111" id="fnref111"><sup>111</sup></a> mistrust of vaccines or public health officials,<a class="footnoteRef" href="#fn112" id="fnref112"><sup>112</sup></a> and believing that the risks associated with vaccines are greater than those associated with infection.<a class="footnoteRef" href="#fn113" id="fnref113"><sup>113</sup></a><a class="footnoteRef" href="#fn114" id="fnref114"><sup>114</sup></a><a class="footnoteRef" href="#fn115" id="fnref115"><sup>115</sup></a><a class="footnoteRef" href="#fn116" id="fnref116"><sup>116</sup></a> Individuals are more likely to free ride if vaccination rates are high enough so as to convince a person that he or she may not need to be immune since a sufficient number of others already are.<a class="footnoteRef" href="#fn117" id="fnref117"><sup>117</sup></a><a class="footnoteRef" href="#fn118" id="fnref118"><sup>118</sup></a> If large numbers of people behave in this manner, then herd immunity in the community will be lost.<a class="footnoteRef" href="#fn119" id="fnref119"><sup>119</sup></a><a class="footnoteRef" href="#fn120" id="fnref120"><sup>120</sup></a></p>
<h2 id="mechanism">Mechanism</h2>
<table>
<tbody>
<tr class="odd">
<td style="text-align: left;">

<p><strong>Estimated <em>R</em><sub>0</sub> and HITs of well-known infectious diseases</strong><a class="footnoteRef" href="#fn121" id="fnref121"><sup>121</sup></a></p></td>
<td style="text-align: left;">

<p>Disease</p></td>
<td style="text-align: left;">

<p>Transmission</p></td>
<td style="text-align: left;">

<p><em>R</em><sub>0</sub></p></td>
<td style="text-align: left;">

<p>HIT</p></td>
</tr>
<tr class="even">
<td style="text-align: left;">

<p><a class="uri" href="Measles" title="wikilink">Measles</a></p></td>
<td style="text-align: left;">

<p>Airborne</p></td>
<td style="text-align: left;">

<p>12–18</p></td>
<td style="text-align: left;">

<p>92–95%</p></td>
</tr>
<tr class="odd">
<td style="text-align: left;">

<p><a class="uri" href="Pertussis" title="wikilink">Pertussis</a></p></td>
<td style="text-align: left;">

<p>Airborne droplet</p></td>
<td style="text-align: left;">

<p>12–17<a class="footnoteRef" href="#fn122" id="fnref122"><sup>122</sup></a></p></td>
<td style="text-align: left;">

<p>92–94%</p></td>
</tr>
<tr class="even">
<td style="text-align: left;">

<p><a class="uri" href="Diphtheria" title="wikilink">Diphtheria</a></p></td>
<td style="text-align: left;">

<p>Saliva</p></td>
<td style="text-align: left;">

<p>6–7</p></td>
<td style="text-align: left;">

<p>83–86%</p></td>
</tr>
<tr class="odd">
<td style="text-align: left;">

<p><a class="uri" href="Rubella" title="wikilink">Rubella</a></p></td>
<td style="text-align: left;">

<p>Airborne droplet</p></td>
</tr>
<tr class="even">
<td style="text-align: left;">

<p><a class="uri" href="Smallpox" title="wikilink">Smallpox</a></p></td>
<td style="text-align: left;">

<p>5–7</p></td>
<td style="text-align: left;">

<p>80–86%</p></td>
</tr>
<tr class="odd">
<td style="text-align: left;">

<p><a class="uri" href="Polio" title="wikilink">Polio</a></p></td>
<td style="text-align: left;">

<p>Fecal-oral route</p></td>
</tr>
<tr class="even">
<td style="text-align: left;">

<p><a class="uri" href="Mumps" title="wikilink">Mumps</a></p></td>
<td style="text-align: left;">

<p>Airborne droplet</p></td>
<td style="text-align: left;">

<p>4–7</p></td>
<td style="text-align: left;">

<p>75–86%</p></td>
</tr>
<tr class="odd">
<td style="text-align: left;">

<p><a class="uri" href="SARS" title="wikilink">SARS</a></p></td>
<td style="text-align: left;">

<p>2–5<a class="footnoteRef" href="#fn123" id="fnref123"><sup>123</sup></a></p></td>
<td style="text-align: left;">

<p>50–80%</p></td>
</tr>
<tr class="even">
<td style="text-align: left;">

<p><a href="Ebola_virus_disease" title="wikilink">Ebola</a><br/>
<small>(<a href="Ebola_virus_epidemic_in_West_Africa" title="wikilink">Ebola virus epidemic in West Africa</a>)</small></p></td>
<td style="text-align: left;">

<p>Bodily fluids</p></td>
<td style="text-align: left;">

<p>1.5–2.5<a class="footnoteRef" href="#fn124" id="fnref124"><sup>124</sup></a></p></td>
<td style="text-align: left;">

<p>33–60%</p></td>
</tr>
<tr class="odd">
<td style="text-align: left;">

<p><a class="uri" href="Influenza" title="wikilink">Influenza</a><br/>
<small>(<a href="influenza_pandemic" title="wikilink">influenza pandemics</a>)</small></p></td>
<td style="text-align: left;">

<p>Airborne droplet</p></td>
<td style="text-align: left;">

<p>1.5–1.8<a class="footnoteRef" href="#fn125" id="fnref125"><sup>125</sup></a></p></td>
<td style="text-align: left;">

<p>33–44%</p></td>
</tr>
</tbody>
</table>

<p>Individuals who are immune to a disease act as a barrier in the spread of disease, slowing or preventing the transmission of disease to others.<a class="footnoteRef" href="#fn126" id="fnref126"><sup>126</sup></a> An individual's immunity can be acquired via a natural infection or through artificial means, such as vaccination.<a class="footnoteRef" href="#fn127" id="fnref127"><sup>127</sup></a> When a critical proportion of the population becomes immune, called the <em>herd immunity threshold</em> (HIT) or <em>herd immunity level</em> (HIL), the disease may no longer persist in the population, ceasing to be <a class="uri" href="endemic" title="wikilink">endemic</a>.<a class="footnoteRef" href="#fn128" id="fnref128"><sup>128</sup></a><a class="footnoteRef" href="#fn129" id="fnref129"><sup>129</sup></a> This threshold can be calculated by taking <em>R</em><sub>0</sub>, the <a href="basic_reproduction_number" title="wikilink">basic reproduction number</a>, or the average number of new infections caused by each case in an entirely susceptible population that is homogeneous, or well-mixed, meaning each individual can come into contact with every other susceptible individual in the population,<a class="footnoteRef" href="#fn130" id="fnref130"><sup>130</sup></a><a class="footnoteRef" href="#fn131" id="fnref131"><sup>131</sup></a><a class="footnoteRef" href="#fn132" id="fnref132"><sup>132</sup></a> and multiplying it by <em>S</em>, the proportion of the population who are susceptible to infection:</p>

<p>
<math display="block" id="Herd_immunity:0">
<semantics>
<mrow>
<mrow>
<msub>
<mpadded lspace="5pt" width="+5pt">
<mi>R</mi>
</mpadded>
<mn>0</mn>
</msub>
<mo>⋅</mo>
<mi>S</mi>
</mrow>
<mo>=</mo>
<mn>1.</mn>
</mrow>
<annotation-xml encoding="MathML-Content">
<apply>
<eq></eq>
<apply>
<ci>normal-⋅</ci>
<apply>
<csymbol cd="ambiguous">subscript</csymbol>
<ci>R</ci>
<cn type="integer">0</cn>
</apply>
<ci>S</ci>
</apply>
<cn type="float">1.</cn>
</apply>
</annotation-xml>
<annotation encoding="application/x-tex">
   \ R_{0}\cdot S=1.
  </annotation>
</semantics>
</math>
</p>

<p><em>S</em> can be rewritten as (1 - <em>p</em>) because <em>p</em> is the proportion of the population that is immune and <em>p</em> + <em>S</em> equals one. Then, the equation can be rearranged to place <em>p</em> by itself as follows:</p>

<p>
<math display="block" id="Herd_immunity:1">
<semantics>
<mrow>
<mrow>
<mrow>
<msub>
<mpadded lspace="5pt" width="+5pt">
<mi>R</mi>
</mpadded>
<mn>0</mn>
</msub>
<mo>⋅</mo>
<mrow>
<mo stretchy="false">(</mo>
<mrow>
<mn>1</mn>
<mo>-</mo>
<mi>p</mi>
</mrow>
<mo stretchy="false">)</mo>
</mrow>
</mrow>
<mo>=</mo>
<mn>1</mn>
</mrow>
<mo>,</mo>
</mrow>
<annotation-xml encoding="MathML-Content">
<apply>
<eq></eq>
<apply>
<ci>normal-⋅</ci>
<apply>
<csymbol cd="ambiguous">subscript</csymbol>
<ci>R</ci>
<cn type="integer">0</cn>
</apply>
<apply>
<minus></minus>
<cn type="integer">1</cn>
<ci>p</ci>
</apply>
</apply>
<cn type="integer">1</cn>
</apply>
</annotation-xml>
<annotation encoding="application/x-tex">
   \ R_{0}\cdot(1-p)=1,
  </annotation>
</semantics>
</math>

 → 

<math display="inline" id="Herd_immunity:2">
<semantics>
<mrow>
<mrow>
<mrow>
<mn>1</mn>
<mo>-</mo>
<mi>p</mi>
</mrow>
<mo>=</mo>
<mfrac>
<mn>1</mn>
<msub>
<mi>R</mi>
<mn>0</mn>
</msub>
</mfrac>
</mrow>
<mo>,</mo>
</mrow>
<annotation-xml encoding="MathML-Content">
<apply>
<eq></eq>
<apply>
<minus></minus>
<cn type="integer">1</cn>
<ci>p</ci>
</apply>
<apply>
<divide></divide>
<cn type="integer">1</cn>
<apply>
<csymbol cd="ambiguous">subscript</csymbol>
<ci>R</ci>
<cn type="integer">0</cn>
</apply>
</apply>
</apply>
</annotation-xml>
<annotation encoding="application/x-tex">
   1-p=\frac{1}{R_{0}},
  </annotation>
</semantics>
</math>

 → 

<math display="inline" id="Herd_immunity:3">
<semantics>
<mrow>
<mrow>
<msub>
<mi>p</mi>
<mi>c</mi>
</msub>
<mo>=</mo>
<mrow>
<mn>1</mn>
<mo>-</mo>
<mfrac>
<mn>1</mn>
<msub>
<mi>R</mi>
<mn>0</mn>
</msub>
</mfrac>
</mrow>
</mrow>
<mo>.</mo>
</mrow>
<annotation-xml encoding="MathML-Content">
<apply>
<eq></eq>
<apply>
<csymbol cd="ambiguous">subscript</csymbol>
<ci>p</ci>
<ci>c</ci>
</apply>
<apply>
<minus></minus>
<cn type="integer">1</cn>
<apply>
<divide></divide>
<cn type="integer">1</cn>
<apply>
<csymbol cd="ambiguous">subscript</csymbol>
<ci>R</ci>
<cn type="integer">0</cn>
</apply>
</apply>
</apply>
</apply>
</annotation-xml>
<annotation encoding="application/x-tex">
   p_{c}=1-\frac{1}{R_{0}}.
  </annotation>
</semantics>
</math>
</p>

<p>With <em>p</em> being by itself on the left side of the equation, it can now be written as <em>p</em><sub>c</sub> to represent the critical proportion of the population needed to become immune to stop the transmission of disease, or the herd immunity threshold.<a class="footnoteRef" href="#fn133" id="fnref133"><sup>133</sup></a> <em>R</em><sub>0</sub> functions as a measure of contagiousness, so low <em>R</em><sub>0</sub> values are associated with lower HITs needed, whereas higher <em>R</em><sub>0</sub>s demand higher HITs.<a class="footnoteRef" href="#fn134" id="fnref134"><sup>134</sup></a><a class="footnoteRef" href="#fn135" id="fnref135"><sup>135</sup></a> For example, a disease with an <em>R</em><sub>0</sub> of 2 theoretically needs only a 50% HIT to be eliminated, whereas a disease with an <em>R</em><sub>0</sub> of 10 needs a 90% HIT.<a class="footnoteRef" href="#fn136" id="fnref136"><sup>136</sup></a> These calculations assume that the entire population is susceptible, meaning no individuals are immune to the disease. In reality, varying proportions of the population are immune to any given disease at any given time.<a class="footnoteRef" href="#fn137" id="fnref137"><sup>137</sup></a> To account for this, the effective reproductive number <em>R</em><sub>e</sub>, also written as <em>R</em><sub>t</sub>, or the average number of infections caused at time <em>t</em>, can found by multiplying <em>R</em><sub>0</sub> by the fraction of the population that is still susceptible. When <em>R</em><sub>e</sub> is reduced to and sustained below 1, the number of cases occurring in the population gradually decreases until the disease has been eliminated.<a class="footnoteRef" href="#fn138" id="fnref138"><sup>138</sup></a><a class="footnoteRef" href="#fn139" id="fnref139"><sup>139</sup></a><a class="footnoteRef" href="#fn140" id="fnref140"><sup>140</sup></a> If a population is immune to a disease in excess of that disease's HIT, then the number of cases will reduce at a faster rate, outbreaks will be even less likely to happen, and outbreaks that do occur will be smaller than they otherwise would be.<a class="footnoteRef" href="#fn141" id="fnref141"><sup>141</sup></a><a class="footnoteRef" href="#fn142" id="fnref142"><sup>142</sup></a> If <em>R</em><sub>e</sub> increases to above 1, then the disease is neither in a steady state nor decreasing in <a href="Incidence_(epidemiology)" title="wikilink">incidence</a> but is actively spreading through the population and infecting a larger number of people than usual.<a class="footnoteRef" href="#fn143" id="fnref143"><sup>143</sup></a><a class="footnoteRef" href="#fn144" id="fnref144"><sup>144</sup></a></p>

<p>A second assumption made by these calculations is that populations are homogeneous, or well-mixed, when in reality populations are better described as social networks as individuals tend to cluster together, remaining in relatively close contact with a limited number of other individuals. In these networks, transmission only occurs between those who are geographically or physically close to one another.<a class="footnoteRef" href="#fn145" id="fnref145"><sup>145</sup></a><a class="footnoteRef" href="#fn146" id="fnref146"><sup>146</sup></a><a class="footnoteRef" href="#fn147" id="fnref147"><sup>147</sup></a> The shape and size of a network is likely to alter a disease's HIT, making incidence either more or less common.<a class="footnoteRef" href="#fn148" id="fnref148"><sup>148</sup></a><a class="footnoteRef" href="#fn149" id="fnref149"><sup>149</sup></a> In heterogeneous populations, <em>R</em><sub>0</sub> is now considered to be a measure of the number of cases generated by a "typical" infectious person, which depends on how individuals within a network interact with each other.<a class="footnoteRef" href="#fn150" id="fnref150"><sup>150</sup></a> Interactions within networks are more common than between networks, in which case the most highly connected networks will transmit disease more easily, resulting in a higher <em>R</em><sub>0</sub> and a higher HIT than would be required in a less connected network.<a class="footnoteRef" href="#fn151" id="fnref151"><sup>151</sup></a><a class="footnoteRef" href="#fn152" id="fnref152"><sup>152</sup></a> In networks that either opt not to become immune or are not immunized sufficiently, diseases may persist despite not existing in better-immunized networks.<a class="footnoteRef" href="#fn153" id="fnref153"><sup>153</sup></a></p>
<h2 id="boosts">Boosts</h2>
<h3 id="vaccination">Vaccination</h3>

<p>The primary way to boost herd immunity is through the use of vaccines.<a class="footnoteRef" href="#fn154" id="fnref154"><sup>154</sup></a><a class="footnoteRef" href="#fn155" id="fnref155"><sup>155</sup></a> Their use is originally based on the observation that milkmaids exposed to <a class="uri" href="cowpox" title="wikilink">cowpox</a> were immune to smallpox, so the practice of <a class="uri" href="inoculating" title="wikilink">inoculating</a> people with the cowpox virus began as a way to prevent smallpox cases.<a class="footnoteRef" href="#fn156" id="fnref156"><sup>156</sup></a> Well-developed vaccines provide protection in a far safer way than natural infections, as vaccines generally do not cause the diseases they protect against and severe adverse effects are significantly less common than complications from natural infections.<a class="footnoteRef" href="#fn157" id="fnref157"><sup>157</sup></a><a class="footnoteRef" href="#fn158" id="fnref158"><sup>158</sup></a> The <a href="immune_system" title="wikilink">immune system</a> does not distinguish between natural infections and vaccines, forming an <a href="Immunity_(medical)#Active_immunity" title="wikilink">active response</a> to both, so immunity induced via vaccination is similar to what would have occurred from contracting and recovering from the disease.<a class="footnoteRef" href="#fn159" id="fnref159"><sup>159</sup></a> In order to achieve herd immunity through vaccination, vaccine manufacturers aim to produce vaccines with low failure rates and policy makers aim to encourage their use.<a class="footnoteRef" href="#fn160" id="fnref160"><sup>160</sup></a> After the successful introduction and widespread use of a vaccine, sharp declines in the incidence of diseases it protects against can observed, necessarily decreasing the number of hospitalizations and deaths caused by such diseases.<a class="footnoteRef" href="#fn161" id="fnref161"><sup>161</sup></a><a class="footnoteRef" href="#fn162" id="fnref162"><sup>162</sup></a><a class="footnoteRef" href="#fn163" id="fnref163"><sup>163</sup></a></p>

<p>Assuming a vaccine is 100% effective, then the equation used for calculating the herd immunity threshold can be used for calculating the vaccination level needed to eliminate a disease, written as <em>V</em><sub>c</sub>.<a class="footnoteRef" href="#fn164" id="fnref164"><sup>164</sup></a> Vaccines are usually imperfect however, so the effectiveness, <em>E</em>, of a vaccine must be accounted for:</p>

<p>
<math display="block" id="Herd_immunity:4">
<semantics>
<mrow>
<mrow>
<msub>
<mi>V</mi>
<mi>c</mi>
</msub>
<mo>=</mo>
<mfrac>
<mrow>
<mn>1</mn>
<mo>-</mo>
<mfrac>
<mn>1</mn>
<msub>
<mi>R</mi>
<mn>0</mn>
</msub>
</mfrac>
</mrow>
<mi>E</mi>
</mfrac>
</mrow>
<mo>.</mo>
</mrow>
<annotation-xml encoding="MathML-Content">
<apply>
<eq></eq>
<apply>
<csymbol cd="ambiguous">subscript</csymbol>
<ci>V</ci>
<ci>c</ci>
</apply>
<apply>
<divide></divide>
<apply>
<minus></minus>
<cn type="integer">1</cn>
<apply>
<divide></divide>
<cn type="integer">1</cn>
<apply>
<csymbol cd="ambiguous">subscript</csymbol>
<ci>R</ci>
<cn type="integer">0</cn>
</apply>
</apply>
</apply>
<ci>E</ci>
</apply>
</apply>
</annotation-xml>
<annotation encoding="application/x-tex">
   V_{c}=\frac{1-\frac{1}{R_{0}}}{E}.
  </annotation>
</semantics>
</math>
</p>

<p>From this equation, it can be observed that if <em>E</em> is less than (1 − 1/<em>R</em><sub>0</sub>), then it will be impossible to eliminate a disease even if the entire population is vaccinated.<a class="footnoteRef" href="#fn165" id="fnref165"><sup>165</sup></a> Similarly, waning vaccine-induced immunity, as occurs with <a href="DPT_vaccine#Combination_vaccines_with_acellular_pertussis" title="wikilink">acellular pertussis vaccines</a>, requires higher levels of booster vaccination in order to sustain herd immunity.<a class="footnoteRef" href="#fn166" id="fnref166"><sup>166</sup></a><a class="footnoteRef" href="#fn167" id="fnref167"><sup>167</sup></a> If a disease has ceased to be endemic to a population, then natural infections will no longer contribute to a reduction in the fraction of the population that is susceptible; only vaccination will contribute to this reduction.<a class="footnoteRef" href="#fn168" id="fnref168"><sup>168</sup></a> The relation between vaccine coverage and effectiveness and disease incidence can be shown by subtracting the product of the effectiveness of a vaccine and the proportion of the population that is vaccinated, <em>p</em><sub>v</sub>, from the herd immunity threshold equation as follows: </p>

<p>
<math display="block" id="Herd_immunity:5">
<semantics>
<mrow>
<mrow>
<mrow>
<mo stretchy="false">(</mo>
<mrow>
<mn>1</mn>
<mo>-</mo>
<mfrac>
<mn>1</mn>
<msub>
<mi>R</mi>
<mn>0</mn>
</msub>
</mfrac>
</mrow>
<mo stretchy="false">)</mo>
</mrow>
<mo>-</mo>
<mrow>
<mo stretchy="false">(</mo>
<mrow>
<mi>E</mi>
<mo>×</mo>
<msub>
<mi>p</mi>
<mi>v</mi>
</msub>
</mrow>
<mo stretchy="false">)</mo>
</mrow>
</mrow>
<mo>.</mo>
</mrow>
<annotation-xml encoding="MathML-Content">
<apply>
<minus></minus>
<apply>
<minus></minus>
<cn type="integer">1</cn>
<apply>
<divide></divide>
<cn type="integer">1</cn>
<apply>
<csymbol cd="ambiguous">subscript</csymbol>
<ci>R</ci>
<cn type="integer">0</cn>
</apply>
</apply>
</apply>
<apply>
<times></times>
<ci>E</ci>
<apply>
<csymbol cd="ambiguous">subscript</csymbol>
<ci>p</ci>
<ci>v</ci>
</apply>
</apply>
</apply>
</annotation-xml>
<annotation encoding="application/x-tex">
   (1-\frac{1}{R_{0}})-(E\times p_{v}).
  </annotation>
</semantics>
</math>
</p>

<p>It can be observed from this equation that, <em><a href="ceteris_paribus" title="wikilink">ceteris paribus</a></em>, any increase in either vaccine coverage or vaccine effectiveness, including any increase in excess of a disease's HIT, further reduces the number of cases of a disease.<a class="footnoteRef" href="#fn169" id="fnref169"><sup>169</sup></a> The rate of decline in cases depends on a disease's <em>R</em><sub>0</sub>, with diseases with lower <em>R</em><sub>0</sub> values experiencing sharper declines.<a class="footnoteRef" href="#fn170" id="fnref170"><sup>170</sup></a> Vaccines usually possess at least one <a class="uri" href="contraindication" title="wikilink">contraindication</a> for a specific population for medical reasons, so it is vital for both effectiveness and coverage to be high so that herd immunity can be established to protect these individuals.<a class="footnoteRef" href="#fn171" id="fnref171"><sup>171</sup></a><a class="footnoteRef" href="#fn172" id="fnref172"><sup>172</sup></a><a class="footnoteRef" href="#fn173" id="fnref173"><sup>173</sup></a></p>
<h3 id="passive-immunity">Passive immunity</h3>

<p>The transfer of maternal antibodies, primarily <a href="immunoglobulin_G" title="wikilink">immunoglobulin G</a> antibodies, across the <a class="uri" href="placenta" title="wikilink">placenta</a> helps protect fetuses and newborns from disease.<a class="footnoteRef" href="#fn174" id="fnref174"><sup>174</sup></a><a class="footnoteRef" href="#fn175" id="fnref175"><sup>175</sup></a> After birth, newborns can also acquire these antibodies from <a class="uri" href="colostrum" title="wikilink">colostrum</a>.<a class="footnoteRef" href="#fn176" id="fnref176"><sup>176</sup></a> Since these antibodies provide some degree of protection, newborns are capable of contributing to herd immunity.<a class="footnoteRef" href="#fn177" id="fnref177"><sup>177</sup></a> This contribution, however, is temporary, being gradually lost as the presence of maternal antibodies wanes during the first few months of life.<a class="footnoteRef" href="#fn178" id="fnref178"><sup>178</sup></a><a class="footnoteRef" href="#fn179" id="fnref179"><sup>179</sup></a> The presence of maternal antibodies in a newborn's body often, but not always, adversely affects vaccine effectiveness,<a class="footnoteRef" href="#fn180" id="fnref180"><sup>180</sup></a><a class="footnoteRef" href="#fn181" id="fnref181"><sup>181</sup></a> so additional doses are recommended for some vaccines while others are not first administered to the infant until after such antibodies are no longer present in the body.<a class="footnoteRef" href="#fn182" id="fnref182"><sup>182</sup></a><a class="footnoteRef" href="#fn183" id="fnref183"><sup>183</sup></a> For some diseases that are particularly severe for fetuses and newborns, such as influenza and tetanus, pregnant women may be immunized in order to transfer antibodies to the child.<a class="footnoteRef" href="#fn184" id="fnref184"><sup>184</sup></a><a class="footnoteRef" href="#fn185" id="fnref185"><sup>185</sup></a><a class="footnoteRef" href="#fn186" id="fnref186"><sup>186</sup></a></p>

<p>In contrast to natural passive immunity, acquired passive immunity refers to the process of obtaining <a href="Serum_(blood)" title="wikilink">serum</a> or <a href="Blood_plasma" title="wikilink">plasma</a> from immune individuals, then taking antibodies from this and injecting it to protect certain susceptible persons.<a class="footnoteRef" href="#fn187" id="fnref187"><sup>187</sup></a><a class="footnoteRef" href="#fn188" id="fnref188"><sup>188</sup></a> High-risk groups that are either more likely to become infected or are more likely to experience complications from infection may receive antibody preparations to prevent these infections or to reduce the severity of symptoms.<a class="footnoteRef" href="#fn189" id="fnref189"><sup>189</sup></a> As with natural passive immunity, protection is immediate but wanes over time, so any contribution to herd immunity from acquired passive immunity is temporary.<a class="footnoteRef" href="#fn190" id="fnref190"><sup>190</sup></a><a class="footnoteRef" href="#fn191" id="fnref191"><sup>191</sup></a><a class="footnoteRef" href="#fn192" id="fnref192"><sup>192</sup></a> <a class="uri" href="Antiserum" title="wikilink">Antiserum</a>, especially from animals, is often administered with caution because the immune system may consider the antibodies to be harmful and trigger a response to it, called <a href="serum_sickness" title="wikilink">serum sickness</a>.<a class="footnoteRef" href="#fn193" id="fnref193"><sup>193</sup></a></p>
<h2 id="history">History</h2>

<p> Although first described in 1923,<a class="footnoteRef" href="#fn194" id="fnref194"><sup>194</sup></a> herd immunity was first recognized as a naturally occurring phenomenon in the 1930s when A. W. Hedrich published research on the <a class="uri" href="epidemiology" title="wikilink">epidemiology</a> of measles in <a class="uri" href="Baltimore" title="wikilink">Baltimore</a> and took notice that after many children had become immune to measles, the number of new infections temporarily decreased, including among susceptible children.<a class="footnoteRef" href="#fn195" id="fnref195"><sup>195</sup></a><a class="footnoteRef" href="#fn196" id="fnref196"><sup>196</sup></a> In spite of this knowledge, efforts to control and eliminate measles were unsuccessful until mass vaccination using the measles vaccine began in the 1960s.<a class="footnoteRef" href="#fn197" id="fnref197"><sup>197</sup></a><a class="footnoteRef" href="#fn198" id="fnref198"><sup>198</sup></a> Mass vaccination, discussions of disease eradication, and cost-benefit analyses of vaccination subsequently prompted more widespread use of the term <em>herd immunity</em>.<a class="footnoteRef" href="#fn199" id="fnref199"><sup>199</sup></a> In the 1970s, the theorem used to calculated a disease's herd immunity threshold was developed.<a class="footnoteRef" href="#fn200" id="fnref200"><sup>200</sup></a> During the <a href="Smallpox#Eradication" title="wikilink">smallpox eradication campaign</a> in the 1960s and 1970s, the practice of <em><a href="ring_vaccination" title="wikilink">ring vaccination</a></em>, of which herd immunity is integral to, began as a way to immunize every person in a "ring" around an infected individual to prevent outbreaks from spreading.<a class="footnoteRef" href="#fn201" id="fnref201"><sup>201</sup></a></p>

<p>Since the adoption of mass and ring vaccination, complexities and challenges to herd immunity have arisen.<a class="footnoteRef" href="#fn202" id="fnref202"><sup>202</sup></a><a class="footnoteRef" href="#fn203" id="fnref203"><sup>203</sup></a> Modelling of the spread of infectious disease originally made a number of assumptions, namely that entire populations are susceptible and well-mixed, which do not exist in reality, so more precise equations have been developed.<a class="footnoteRef" href="#fn204" id="fnref204"><sup>204</sup></a> In recent decades, it has been recognized that the dominant strain of a microorganism in circulation may change due to herd immunity, either because of herd immunity acting as an evolutionary pressure or because herd immunity against one strain allowed another already-existing strain to spread.<a class="footnoteRef" href="#fn205" id="fnref205"><sup>205</sup></a><a class="footnoteRef" href="#fn206" id="fnref206"><sup>206</sup></a> Emerging or ongoing <a href="vaccine_controversies" title="wikilink">vaccine controversies</a> and various reasons for opposing vaccination have made herd immunity to either not be established or to disappear in certain communities, allowing preventable diseases to persist in or return to these communities.<a class="footnoteRef" href="#fn207" id="fnref207"><sup>207</sup></a><a class="footnoteRef" href="#fn208" id="fnref208"><sup>208</sup></a><a class="footnoteRef" href="#fn209" id="fnref209"><sup>209</sup></a></p>
<h2 id="see-also">See also</h2>
<ul>
<li><a class="uri" href="Premunity" title="wikilink">Premunity</a></li>
</ul>
<h2 id="references">References</h2>
<h2 id="external-links">External links</h2>
<ul>
<li><a href="http://www.mathepi.com/maindir/herd.html">Mathematical epidemiology information</a></li>
<li><a href="http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ije/vol5n1/population.xml">Changes In Population Parameters On The Herd Immunity Threshold</a></li>
<li><a href="http://www.software3d.com/Home/Vax/Immunity.php">A visual simulation of herd immunity</a> written by Shane Killian and modified by Robert Webb</li>
</ul>

<p>"</p>

<p><a class="uri" href="Category:Epidemiology" title="wikilink">Category:Epidemiology</a> <a class="uri" href="Category:Immunology" title="wikilink">Category:Immunology</a> <a class="uri" href="Category:Prevention" title="wikilink">Category:Prevention</a> <a href="Category:Public_health" title="wikilink">Category:Public health</a> <a class="uri" href="Category:Vaccination" title="wikilink">Category:Vaccination</a></p>
<section class="footnotes">
<hr/>
<ol>
<li id="fn1"><a href="#fnref1">↩</a></li>
<li id="fn2"><a href="#fnref2">↩</a></li>
<li id="fn3"><a href="#fnref3">↩</a></li>
<li id="fn4"></li>
<li id="fn5"></li>
<li id="fn6"><a href="#fnref6">↩</a></li>
<li id="fn7"><a href="#fnref7">↩</a></li>
<li id="fn8"></li>
<li id="fn9"><a href="#fnref9">↩</a></li>
<li id="fn10"><a href="#fnref10">↩</a></li>
<li id="fn11"></li>
<li id="fn12"></li>
<li id="fn13"></li>
<li id="fn14"><a href="#fnref14">↩</a></li>
<li id="fn15"><a href="#fnref15">↩</a></li>
<li id="fn16"><a href="#fnref16">↩</a></li>
<li id="fn17"><a href="#fnref17">↩</a></li>
<li id="fn18"><a href="#fnref18">↩</a></li>
<li id="fn19"><a href="#fnref19">↩</a></li>
<li id="fn20"></li>
<li id="fn21"></li>
<li id="fn22"></li>
<li id="fn23"><a href="#fnref23">↩</a></li>
<li id="fn24"><a href="#fnref24">↩</a></li>
<li id="fn25"><a href="#fnref25">↩</a></li>
<li id="fn26"><a href="#fnref26">↩</a></li>
<li id="fn27"><a href="#fnref27">↩</a></li>
<li id="fn28"></li>
<li id="fn29"></li>
<li id="fn30"></li>
<li id="fn31"></li>
<li id="fn32"><a href="#fnref32">↩</a></li>
<li id="fn33"></li>
<li id="fn34"><a href="#fnref34">↩</a></li>
<li id="fn35"><a href="#fnref35">↩</a></li>
<li id="fn36"></li>
<li id="fn37"></li>
<li id="fn38"><a href="#fnref38">↩</a></li>
<li id="fn39"></li>
<li id="fn40"></li>
<li id="fn41"></li>
<li id="fn42"><a href="#fnref42">↩</a></li>
<li id="fn43"><a href="#fnref43">↩</a></li>
<li id="fn44"></li>
<li id="fn45"><a href="#fnref45">↩</a></li>
<li id="fn46"></li>
<li id="fn47"></li>
<li id="fn48"><a href="#fnref48">↩</a></li>
<li id="fn49"><a href="#fnref49">↩</a></li>
<li id="fn50"><a href="#fnref50">↩</a></li>
<li id="fn51"></li>
<li id="fn52"><a href="#fnref52">↩</a></li>
<li id="fn53"><a href="#fnref53">↩</a></li>
<li id="fn54"></li>
<li id="fn55"></li>
<li id="fn56"></li>
<li id="fn57"></li>
<li id="fn58"></li>
<li id="fn59"></li>
<li id="fn60"></li>
<li id="fn61"></li>
<li id="fn62"></li>
<li id="fn63"></li>
<li id="fn64"><a href="#fnref64">↩</a></li>
<li id="fn65"><a href="#fnref65">↩</a></li>
<li id="fn66"><a href="#fnref66">↩</a></li>
<li id="fn67"><a href="#fnref67">↩</a></li>
<li id="fn68"></li>
<li id="fn69"><a href="#fnref69">↩</a></li>
<li id="fn70"></li>
<li id="fn71"></li>
<li id="fn72"></li>
<li id="fn73"></li>
<li id="fn74"></li>
<li id="fn75"><a href="#fnref75">↩</a></li>
<li id="fn76"><a href="#fnref76">↩</a></li>
<li id="fn77"><a href="#fnref77">↩</a></li>
<li id="fn78"><a href="#fnref78">↩</a></li>
<li id="fn79"></li>
<li id="fn80"></li>
<li id="fn81"></li>
<li id="fn82"></li>
<li id="fn83"></li>
<li id="fn84"></li>
<li id="fn85"><a href="#fnref85">↩</a></li>
<li id="fn86"></li>
<li id="fn87"><a href="#fnref87">↩</a></li>
<li id="fn88"></li>
<li id="fn89"></li>
<li id="fn90"></li>
<li id="fn91"></li>
<li id="fn92"></li>
<li id="fn93"></li>
<li id="fn94"></li>
<li id="fn95"><a href="#fnref95">↩</a></li>
<li id="fn96"></li>
<li id="fn97"><a href="#fnref97">↩</a></li>
<li id="fn98"><a href="#fnref98">↩</a></li>
<li id="fn99"><a href="#fnref99">↩</a></li>
<li id="fn100"><a href="#fnref100">↩</a></li>
<li id="fn101"><a href="#fnref101">↩</a></li>
<li id="fn102"><a href="#fnref102">↩</a></li>
<li id="fn103"></li>
<li id="fn104"></li>
<li id="fn105"></li>
<li id="fn106"></li>
<li id="fn107"></li>
<li id="fn108"><a href="#fnref108">↩</a></li>
<li id="fn109"><a href="#fnref109">↩</a></li>
<li id="fn110"></li>
<li id="fn111"></li>
<li id="fn112"><a href="#fnref112">↩</a></li>
<li id="fn113"></li>
<li id="fn114"></li>
<li id="fn115"></li>
<li id="fn116"></li>
<li id="fn117"></li>
<li id="fn118"></li>
<li id="fn119"></li>
<li id="fn120"></li>
<li id="fn121">Unless noted, <em>R</em><sub>0</sub> values are from: <a href="http://www.bt.cdc.gov/agent/smallpox/training/overview/pdf/eradicationhistory.pdf">History and Epidemiology of Global Smallpox Eradication</a> From the training course titled "Smallpox: Disease, Prevention, and Intervention". The <a href="Centers_for_Disease_Control_and_Prevention" title="wikilink">Centers for Disease Control and Prevention</a> and the <a href="World_Health_Organization" title="wikilink">World Health Organization</a>. Slide 17. Retrieved 13 March 2015.<a href="#fnref121">↩</a></li>
<li id="fn122"><a href="#fnref122">↩</a></li>
<li id="fn123"><a href="#fnref123">↩</a></li>
<li id="fn124"><a href="#fnref124">↩</a></li>
<li id="fn125"></li>
<li id="fn126"></li>
<li id="fn127"></li>
<li id="fn128"></li>
<li id="fn129"></li>
<li id="fn130"></li>
<li id="fn131"></li>
<li id="fn132"></li>
<li id="fn133"></li>
<li id="fn134"></li>
<li id="fn135"></li>
<li id="fn136"></li>
<li id="fn137"></li>
<li id="fn138"></li>
<li id="fn139"></li>
<li id="fn140"><a href="#fnref140">↩</a></li>
<li id="fn141"></li>
<li id="fn142"></li>
<li id="fn143"></li>
<li id="fn144"></li>
<li id="fn145"></li>
<li id="fn146"></li>
<li id="fn147"></li>
<li id="fn148"></li>
<li id="fn149"></li>
<li id="fn150"></li>
<li id="fn151"></li>
<li id="fn152"></li>
<li id="fn153"></li>
<li id="fn154"></li>
<li id="fn155"><a href="#fnref155">↩</a></li>
<li id="fn156"></li>
<li id="fn157"><a href="#fnref157">↩</a></li>
<li id="fn158"><a href="#fnref158">↩</a></li>
<li id="fn159"><a href="#fnref159">↩</a></li>
<li id="fn160"></li>
<li id="fn161"><a href="#fnref161">↩</a></li>
<li id="fn162"><a href="#fnref162">↩</a></li>
<li id="fn163"><a href="#fnref163">↩</a></li>
<li id="fn164"></li>
<li id="fn165"></li>
<li id="fn166"></li>
<li id="fn167"></li>
<li id="fn168"><a href="#fnref168">↩</a></li>
<li id="fn169"></li>
<li id="fn170"></li>
<li id="fn171"></li>
<li id="fn172"></li>
<li id="fn173"></li>
<li id="fn174"><a href="#fnref174">↩</a></li>
<li id="fn175"><a href="#fnref175">↩</a></li>
<li id="fn176"></li>
<li id="fn177"><a href="#fnref177">↩</a></li>
<li id="fn178"></li>
<li id="fn179"></li>
<li id="fn180"><a href="#fnref180">↩</a></li>
<li id="fn181"><a href="#fnref181">↩</a></li>
<li id="fn182"></li>
<li id="fn183"></li>
<li id="fn184"></li>
<li id="fn185"><a href="#fnref185">↩</a></li>
<li id="fn186"><a href="#fnref186">↩</a></li>
<li id="fn187"></li>
<li id="fn188"><a href="#fnref188">↩</a></li>
<li id="fn189"></li>
<li id="fn190"></li>
<li id="fn191"></li>
<li id="fn192"></li>
<li id="fn193"></li>
<li id="fn194"></li>
<li id="fn195"></li>
<li id="fn196"></li>
<li id="fn197"></li>
<li id="fn198"></li>
<li id="fn199"></li>
<li id="fn200"></li>
<li id="fn201"><a href="#fnref201">↩</a></li>
<li id="fn202"></li>
<li id="fn203"><a href="#fnref203">↩</a></li>
<li id="fn204"></li>
<li id="fn205"></li>
<li id="fn206"></li>
<li id="fn207"></li>
<li id="fn208"></li>
<li id="fn209"></li>
</ol>
</section>
</body>
</html>
